Boothbay Fund Management’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-52,100
| Closed | -$1M | – | 2342 |
|
|
2025
Q3 | $1M | Sell |
52,100
-66,500
| -56% | -$1.19M | 0.01% | 833 |
|
|
2025
Q2 | $2.03M | Buy |
+118,600
| New | +$5.06M | 0.04% | 500 |
|
|
2025
Q1 | – | Sell |
-23,400
| Closed | -$2.85M | – | 1770 |
|
|
2024
Q4 | $2.85M | Buy |
+23,400
| New | +$2.87M | 0.07% | 361 |
|
|
2024
Q3 | – | Sell |
-90,700
| Closed | -$14.3M | – | 1919 |
|
|
2024
Q2 | $14.3M | Sell |
90,700
-241,800
| -73% | -$31.1M | 0.34% | 36 |
|
|
2024
Q1 | $43M | Sell |
332,500
-142,400
| -30% | -$17.4M | 0.83% | 11 |
|
|
2023
Q4 | $45.8M | Buy |
474,900
+250,300
| +111% | +$24M | 1.17% | 3 |
|
|
2023
Q3 | $27.2M | Buy |
224,600
+220,200
| +5,005% | +$24.9M | 0.65% | 13 |
|
|
2023
Q2 | $504K | Sell |
4,400
-38,200
| -90% | -$4.93M | 0.01% | 1097 |
|
|
2023
Q1 | $5.87M | Buy |
+42,600
| New | +$5.53M | 0.12% | 204 |
|
|
2022
Q4 | – | Sell |
-11,500
| Closed | -$1.27M | – | 2423 |
|
|
2022
Q3 | $1.27M | Sell |
11,500
-1,200
| -9% | -$121K | 0.03% | 766 |
|
|
2022
Q2 | $952K | Buy |
+12,700
| New | +$934K | 0.03% | 846 |
|
|
2022
Q1 | – | Sell |
-43,000
| Closed | -$3.87M | – | 2511 |
|
|
2021
Q4 | $3.87M | Buy |
43,000
+7,000
| +19% | +$598K | 0.09% | 264 |
|
|
2021
Q3 | $3.33M | Buy |
36,000
+30,400
| +543% | +$2.34M | 0.09% | 265 |
|
|
2021
Q2 | $435K | Buy |
5,600
+5,483
| +4,686% | +$416K | 0.01% | 1079 |
|
|
2021
Q1 | $872K | Sell |
117
-414
| -78% | -$38.2K | 0.03% | 671 |
|
|
2020
Q4 | $9.05M | Buy |
531
+424
| +396% | +$62.8K | 0.34% | 41 |
|
|
2020
Q3 | $1.5M | Buy |
+107
| New | +$16.3K | 0.09% | 304 |
|
|
2020
Q2 | – | Sell |
-76
| Closed | -$743K | – | 1104 |
|
|
2020
Q1 | $743K | Sell |
76
-89
| -54% | -$10.2K | 0.06% | 364 |
|
|
2019
Q4 | $2.13M | Buy |
+165
| New | +$16.7K | 0.19% | 143 |
|
|
2019
Q3 | – | Sell |
-38
| Closed | -$577K | – | 899 |
|
|
2019
Q2 | $577K | Buy |
38
+18
| +90% | +$2.19K | 0.05% | 376 |
|
|
2019
Q1 | $238K | Buy |
+20
| New | +$2.57K | 0.02% | 570 |
|
|
2018
Q1 | – | Sell |
-877
| Closed | -$4.88M | – | 856 |
|
|
2017
Q4 | $4.88M | Sell |
877
-5
| -0.6% | -$265 | 0.71% | 30 |
|
|
2017
Q3 | $4M | Sell |
882
-30,118
| -97% | -$1.2M | 0.67% | 30 |
|
|
2017
Q2 | $1.04M | Sell |
31,000
-5,600
| -15% | -$182K | 0.22% | 93 |
|
|
2017
Q1 | $1.08M | Buy |
36,600
+26,400
| +259% | +$817K | 0.2% | 115 |
|
|
2016
Q4 | $280 | Buy |
+10,200
| New | +$410K | 0.06% | 424 |
|
Other funds holding SRPT
EAM
Boothbay Fund Management's SRPT Position: Q3 2025 in Review
Boothbay Fund Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 153,460 shares — an estimated $2.74M sold.
Boothbay Fund Management first reported a position in SRPT in Q3 2016 and held it in 14 quarters. The position peaked at $9.06M in Q2 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.
- Boothbay Fund Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
- Boothbay Fund Management sold 153,460 Sarepta Therapeutics shares in Q3 2025, an estimated $2.74M.
- Boothbay Fund Management first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 14 quarters.
- Boothbay Fund Management's Sarepta Therapeutics position peaked at $9.06M in Q2 2024.
- 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.
Based on Boothbay Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.